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A competitive enzyme immunoassay using acetylcholinesterase as tracer for thymosin p4, has been developed. Using this assay and a previously 
described EIA for AcSDKP. a negative regulator of pluripotent haematopoietic stem cell proliferation, the levels of these two peptides were 
determined in mouse tissue extracts. The combination of EIAs with different HPLC procedures validated these methods and clearly demonstrated 
the ubiquity of these pcptides in mouse tissues. Similar results are reported for rabbit thymus which suggest different hypotheses for AcSDKP 
biosynthesis. 
Negative haematopoietic regulator: AcSDKP tetrapeptide; Thymosin 84: Enzyme immunoassay: Acetylcholinesterase: Mouse tissue 
1, INTRODUCTION 
n-Acetyl-Ser-Asp-Lys-Pro (AcSDKP) is a tetrapep- 
tide first isolated from feta1 calf bone marrow in 1977 
[I] and subsequently purified and identified [Zj. It is a 
potent inhibitor of pluripotent haematopoietic stem 
cells (CFU-S)? and hence reduces mortality in mice after 
administration of lethal doses of cytosine arabinoside 
(Ara-C) [3]. In the mouse, AcSDKP is produced in the 
bone marrow [4] and was shown to be a physiological 
regulalor of CFU-S [5]. It also inhibits the entry into 
cycle of fetal or adult rat hepatocytes [6]. It has no effect 
in GM-CFC in the mouse [7]. However. in humans? this 
inhibition occurs in the haematopoietic progenitors of 
normal bone marrow but not in the equivalent leukae- 
mic cells [8]. Using a specific enzyme immunoassay 
@IA), we have recently shown that this peptide is pres- 
cnt in human white blood cells [9]. The peptidc sequence 
AC-S-D-K-P- exists as the N-terminal part of thymosin 
14 (mol. wt. 4963), a thymic polypeptide active in the 
regulation and differentiation of thymus-dcpendcnt 
lymphocytes (for a review see [IO] (Fig. 1), and appears 
to bc an ubiquitous peptide with other unidentified 
basic cellular functions [I 1,121. Rcccntly. it was shown 
that AcSDKP can bc gcneratcd from thymosin fi4 by a 
one-step enzymatic clcavagc in vitro and in vivo [13]. 
A rcccnt report has shown that a polycl~nal antisc- 
rum obtained by coupling an analog (AcSDKPY) to the 
antigcnic carrier was able to ncutralizc the biological 
activity of AcSDKP in mice [l4], To obtain more spcci- 
fit antibodies for AcSDKP, we have developed two 
different strategies for immunogen preparation. One 
involves linkage of the peptide to the antigenic carrier 
via its lysine side chain [9], and the other presented 
here uses linkage of a C terminal elongated peptide 
(AcSDKPDC) via its cysteine side chain. The latter im- 
munogen has been used to obtain antibodies which spe- 
cifically recognize the N-terminal part of thymosin p4 
but not AcSDKP. In the light of these findings, we have 
performed EIA of thymosin p4 using acetylcholinester- 
ase (AChE) as a tracer [ 151. 
We describe here the assay and the distribution of 
AcSDKP and thymosin 84 in mouse tissues and valida- 
tion studies using high-performance liquid chromato- 
graphy (HPLC) combined with EIA measurements. 
2. MATERIALS AND METHODS 
AcSDKP (mol. wt. 487) was kindly provided by Biomcasurc (Hop- 
kinton, MA). Bovine thymosin ,!74 and human thymosin @IO wcrc 
purchased from Peninsula Lab (Mcrscysidc, UK) and thymosin al 
from Bachcm (Bubcndorf. Switzerland). All other synthetic peptidcs 
wcrc synthcsixcd in our laboratory by solid-phase pcptidc technology 
[9]. Oxidation ofths thymosinfi4 form was achicvcd by trcatmcnt with 
H?O: for IX II. Pure AChE (EC 3. I .I .7) was prcparcd from the clcctric 
orpms of the clcctric ccl I~/~l~rrt,/‘hnrrc.r cfwricws ;~nd its activity was 
mc;lsured ;IS previously dcscribcd [l6]. Unlcrs otherwise s~atcd. all 
reagcnta wcrc from Sigm;i (St. Louis. MO) ;md solvents fram Prol;tbo 
(Paris. Frilnce). 131A buffer was a 0.1 M phosphutc buffer PI-I 7,4 
containing (I.‘% N;ICI, Ifi’) M EDTA. 0. I% bovine serum albumin 
and 0.01% sodium iizide. 
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Fig. I, Amino acid sequences of thymosin 84 and thymosin-related peptides (r = rabbit). The regions of homology are boxed. 
Oy (Helsinki, Finland) and microtiter plates Maxisorb from Nunc 
(Roskilde, Denmark). HPLC experiments were performed with a 2249 
LC LKB gradient pump (Bromma, Sweden) and Nucleosil Cl8 
(SFCC, France) and p Bondapack Cl8 (Waters. USA) columns for 
AcSDKP and thymosin 84 separations, respectively. Tissue extracts 
were concentrated by adsorption onto a reverse-phase Cl8 Baker 
column (Phillipsburg. USA) and by a SpeedVacconccntrator SVC 200 
(Savant Instruments Inc., Farmingdale. NY). 
2.3. Antiserrrtn prohctiott 
The preparation of AcSDKP antiserum for these studies has been 
described elsewhere [9]. For thymosin /34 antibody production. 
AcSDKPDC was linked to the maleimidated keyhole limpet hemocya- 
nin (KLH) used as antigcnic carrier. KLH was maleimidated follow- 
ing a procedure described for bovine serum a!bumin (DSA) [17]. 
Briefly, to SO mg of KLH in 5 ml of phosphntc buffer 0.1 M pH7. were 
added 50,umol of N-ethyl malcimide in order to block any tl1iol group. 
The reaction was allowed to proceed for 30 min at 22°C and then I5 
mg (0.5 ml) of A’-succimidyl+V-maleimido methyl) cyclohcxane-l- 
carboxylatc (SMCC) in anydrous dimethylformamide (DMF) was 
added. After 30 min. the mixture was filtered tllrough a G25 column 
(Pharmacia. Sweden) with phosphate buffer (0.1 M pH 6) as eluting 
solvent and stored at -80°C until use. For immunogen preparation, 
20pmol of AcSDKPDC and IOlmol of maleimidated KLH were left 
iC1 react in S ml of phosphate buffer 0.1 M, pH 6 for I h at 30°C and 
18 h at 4°C. The mixture was dialysed against 0.9% NaCI. Five white 
rabbits were immunized and boostercd with 0.8 mg each of immu- 
nogcn following the procedure dcscribcd by Vai’tukaitisctal. [I81 using 
complete Frcund’s adjuvant (Difco, Detroit MI) and subcutaneous 
injections. The rabbits were bled on a weekly basis after the lirst 
booster and after the boosters given cvcry month. One bleeding (L83 I 
SS) was sclcctcd after the fourth booster and kept at 4°C after the 
addition of sodium axidc (0.02% final). 
2.4. Prqtaratiott uf etqnratic trctccr 
Malcimidated G4 form of AChE was used to couple AChE to 
AcSDKPDC following a procedure previously described [ 191. To 0.25 
nmol of malcimidatcd AChE (1 ml) was ad&d 2.5 nmol of 
AcSDKPDC (5 ml), both in phosphate buffer 0. I M pH 6. The rcac- 
tion was allowed to proceed for I 11 at 30°C and 24 h at 4°C. The 
enzymatic conjugate was puriticd by nrolccular sicvc chromatography 
[ 161 and stored at -80°C for scvcral months without loss of cnzymc 
activity or immunorcuctivity. 
Four-wcck.old fwrdc Ihlblc mice wcrc killctl ;~tld the tissues or S 
UllillliilS wcrc rcmovcd, immcdiittely wcighcd, poalcd illld fro;l.cn in 
liquid nitrogen. f:xtractioii was lwrformctl as previously dcsrribcd 
[X), OrgYm wcrc homopcnizcd iIt 2,4”C in 5 ml of6 M gu;midiniunr 
ehloridc using ;III Ultra-Turrax TIX hamogcnixcr (Jnnkc IIII~ Kunkcl. 
Gcrm3ny). The I~omopcniltcr wcrcdilutcd with S ml (lro. I%FfFA ;III~ 
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centrifuged at 18 000 x g for 1 h (LS-50 Beckman, Palo Alto. CA). The 
floating lipid layer was removed and the supernatant passed through 
a Baker Cl8 column. The column had been washed with 5 ml metha- 
nol followed by 5 ml TFA 0.1% prior to loading of the biological 
extracts. After washing with 5 ml 0.1% TFA. the material was eluted 
with 5 ml ofacetonitrilecontaining 0.05% TFA. evaporated to dryness 
and resuspended in EIA buffer or 0.1% TFA for immunological or 
HPLC analysis. respectively. 
2.6. Cotttpetitiw EIA pracedwe 
EIA using acetylcholinesterase for AcSDKP analysis has been de- 
scribed elsewhere [9]. A similar procedure was used for thymosin /$4 
measurements. Briefly, the assay was performed using microtiter 
plates coated with mouse monoclonal anti-rabbit immunoglobulins. 
Enzymatic tracer (0.3 Ellman units/ml [16]), diluted antiserum (L831 
S5 l/40000) and standard or sample all in 50 ~1 EIA buffer, were 
added to each well. After 18-h incubation at 4’C and washing, 200~1 
of enzymatic substrate (Ellman reagent [IG]) were added. One hour 
later the yellow color was automatically measured at 414 nm in each 
well. 
2.7. HPLC crttrr(iqsis qf it?itttutlorecictivc tnoIeriu/ 
In order to validate the nature of the immunoreactivity present in 
the biological samples. HPLC was combined with EIA as described’ 
for AcSDKP analysis in human blood cells and plasma [9]. For thymo- 
sin~4.aminormodificationofthcHPLCprocedurcpreviousl!~dcscrib- 
cd [20] was used. The tissue extracts were cIutcI* frnm the column using 
ditTcrent gradients (reservoir A = 0.1% TFA. reservoir B = acctoni- 
trile. TFA 0.05%). Peptidcs were clutcd using s:!ccessivcly 4% B for 
30 min (Row ratc0.S ml/min). then 4% B to45% B for 55 min and 45% 
B to 100% B for IO min (flow rate I.5 ml/min each. rcspcctivcly). 
Fractions were collected each minute. evaporated to dryness and rc- 
suspcndcd in 0.25 ml EIA bufTcr for assay. 
3. RESULTS AND DISCUSSION 
We have previously described the devclopmcnt of a 
specific and sensitive EIA for AcSDKP [9]. WC report 
hcrc the standard curve (Fig. 2) and a specificity study 
using thymosin-like pcptidcs (Tublc I). As expcctcd in 
the light of the previous data [9], the specificity of 
AcSDKP antibodies is very high since no cross-rcocti- 
vity (CR) with thymosinP4-like pcptidcs w:q obscrvcd. 
in spite of the DKP scqucncc in their N-~crminul region 
(Fig, I). 
The hctcro-bifunc:ional SMCC rcagcnt is now com- 
monly used to link pcptidcs that contain a cystcinc rcsi- 
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Fig. 2. Representative Lo&-Log representation [21] of routine EIA 
standard curves for AcSDKP (x-x) and Thymosin 84 (O-O) assays, 
respectively. B and B. represent he bound enzyme activity measured 
in the presence or absence of competitor. respectively. (Logit B/B, = 
Log( B/B,4 I -BIB,). 
due to proteins [22]. We have previously used this proce- 
dure to obtain an immunoreactive rat atriopeptin- 
AChE conjugate which has allowed the development of 
a highly sensitive immunoassay [19]. This approach led 
us to synthesize the AcSDKPDC peptide in order to 
prepare an immunogen and enzymatic conjugate. Thy- 
mosin p4 was fully recognized by the antibodies result- 
ing in a standard curve (Fig. 1) with a relative high but 
acceptable detection limit of 5 prnol/ml (B/Be 80%), in 
comparison with 0.5 pmol/ml recently described for an- 
other thymosin p4 EIA [23]. where the antiserum was 
obtained by immunization of rabbits with complete thy- 
mosin /?4. Table I shows the specificity of this assay 
analyzed with various peptides. The structural homo- 
logy between AcSDKPDC and the N-terminal part of 
thymosinp4 (AcSDKPDM.. .) (Fig. I) strongly suggests 
that the latter could be the epitope. Nevertheless, epi- 
Cross-rsactivily s1 Ixly 
- 
September 199 1 
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AcSDKP 1 
Fractions (minute) 
Fig. 3. HPLC profiles of immunoreactive synthetic AcSDKP and 
AcADKP peptidcs (A) and mouse thymus extract (B). 
tope size remains a critical factor forthe affinity, since 
a shorter peptide such as AcSDKP is not able to com- 
pete with AcSDKPDC tracer for the antibody (CR = 
0.01%). Also, a discrete change in primary structure 
(alanine instead of serine in the N-terminal part of thy- 
mosin /?lO) can dramatically influence antibody recog- 
nition (CR = 13%). Since oxidized thymosin 84 is fully 
recognized, the methionyl residue cannot be implicated 
in binding with antibody sites. 
3.2. I~llnlurlor’ecrctir~e muterid in tnouse tissues 
Using AcSDKP and thymosin p4 assays, we have 
measured the immunoreactive material present in differ- 
ent mouse tissues (Table II). In each case, the dilution 
GO0 
100 
L? 0, A.0 
0 10 20 30 Id” xl 00 70 00 00 100 
Fractions (minute) 
I:ig. 4. I-IPLC prafilc of rhymnsill/34-like Ill;ltcri;ll ill nwusc lhymus 
cxtrxl. I30vinc lliposin /j4 has llic simc rctciilian tinic (4X mill). 
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Fig. 5. Correlation between the AcSDKP and thymosin 84 levels in 
mouse tissue extracts (r = 0.81). 
curves of biological samples were closely parallel to the 
standard curve (data not shown). The results show 
clearly that the AcSDKP-like material is present in all 
tissues, with a higher concentration in the spleen. This 
is the first evidence of the ubiquity of this peptide in 
mammalian tissues. The same observation has been re- 
ported for thymosin 84 in rat or mouse tissues using 
different analytical procedures such as HPLC [25]. RIA 
[26] and RNA analysis [12]. When the immunoreactive 
materials assayed in each tissue were analyzed by 
HPLC, we observed one immunoreactive peak which 
strictly co-eluted with standards. Fig. 3 and Fig. 4 pre- 
sent the patterns obtained with thymic extract. With 
different AcSDKP and thymosin /I4 levels, the other 
tissues presented the same HPLUEIA profiles. In thy- 
mosin fl4 analysis. a tiny peak was eluted at 100% 
corresponding to an unknown more hydrophobic mate- 
rial (Fig. 4). Taking into account the high specificity of 
EIA and the performance of HPLC separation procedu- 
res [9,27]. we assume that the EIAs measure the true 
AcSDKP and thymosin 84 peptides. respectively. In 
each assay, the level of these two peptides were poorly 
correlated (r = 0.81) (Fig. 5). These results suggest hat 
AcSDKP is synthesized or liberated by pathways or 
cellular events other than those of thymosin 84. This 
hypothesis is prcscntly under invcstigntion in our labo- 
ratory. Among the animal species studied. the rabbit 
possesses a thymosinj4 which differs only in the first 
amino acid (alanine instead of serine) [28]. We found in 
the rabbit thymus 2 and 29.2 nmol/g of AcSDKP and 
thymosin @4-like material, respectively. The immuno- 
chromatograms were exactly the same as those prcscnt- 
ed in Fig, 3 and Fig. 4 for mouse tissue. Since synthetic 
AcSDKP is well scparatcd from AcADKP (Fig. 3A), WC 
assume that the AcSDKP-like material in rabbit thymus 
corresponds to the true AcSDKP molcculc. For thymo- 
sin-like material, if WC take into account the structural 
homology of thymosin 810 (human) and thymosin a4 
(rabbit) (Fig. I), we can expect iI cross-rcuctivity near 
to 10% for thc tuttcr. Cotiscqucntly. the thymosin 84 
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Fractions (minute) 
Fractions (minute) 
Fig. 6. HPLC profiles of immunorcactive synthetic thymosin 84 and 
thymosin/IlO peptides (A) and rabbit thymus extract (B). The HPEC 
procedure is described in ref. 29 (Cl8 column. flow 0.65 mllmin. 
reservoir A: I M formic acid/O.? M pyridine pH 3. reservoir B: n- 
propanol). 
levels in rabbits will be around 300 nmot/g. compared 
to 15.6 nmol/g found by HPLC analysis [29]. This dis- 
crepancy suggests that our assay may measure other 
immunoreactive peptides not detected by our HPLC 
procedure. Rabbit thymosin/I1O(Fig. 1) may be a likely 
candidate, since this peptide is slightly different from 
thymosinp10 [29]. We have here used an HPLC proce- 
dure [29] which allows the separation of thymosin p4 
and thymosinpl0 in rabbit tissue extracts. and synthetic 
thymosin /34 and thymosin /IlO were also separated 
(Fig. GA). When the rabbit thyrnus extract was anatyz- 
Table II 
Contcnr of AcSDKP end thymosin p4 in mouse tissues 
Tissues AcSDKP* Thymosin p4+ 
Thymus 1.64 + 0.68 16.X f: 1.x 
Spleen 3.05 5 I.50 36.6 I 7.5 
Muscls 0.45 f 0.07 3.5 + 0.1 
Brain 0.29 + o,n9 x 2 0.1 
Skin 0.59 ? O,l I 6.9 c 0.4 
Isonc marrow ** I * 0.4 13.x 2 0.s 
Lung 0.86 * 0.25 21.6 Lc I.3 
Liver 0.61 c 0,04 5.4c I 
lnlcslinc I ,Y I * 0.83 18.6 ? 7 
Skmwh I,13 ” (I,24 IX.7 k 1.9 
Kidnq 0.43 ? a.02 6.4 ? 0.2 
Hcirrt 0.88 f 0.36 6.4 ” 2.1 
LUU---WI~-~- -- 
‘Conccnlration (nmol’p) of AcSDKP and Ihymsin /I4 hlcnna of 3 
cxpcrmcnts (S ;Iniinills’~x~rillIrl!l) **pinol;lfl* cells. 
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Fig. 7. Correlation between the tbymosin 84 levels found in mouse 
tissues by EIA and in rat tissues by HPLC (a-*) (r = 0.90) and RIA 
(O-O) (r = 0.98). respectively. 
ed, we observed only one peak which co-eluted with 
standard thymosin84 (Fig. 6B). These data have led us 
to conclude that AcSDKP is also present in the rabbit 
thymus and that if thymosin b4 is involved in the bio- 
synthesis of AcSDKP as recently described [13] for 
mouse, another precursor could be present in rabbit 
tissues. Our EIA for thymosin p4 combined with HPLC 
analysis seems very specific, but a discrepancy is obser- 
ved between the thymosin 84 levels found with our 
assay and those described in the literature for rat tissues 
using HPLC [25] or RIA [26] analysis, even if the corre- 
lation coefficients are high (I’ = 0.90 (n = 8) and Y = 0.98 
(iz = 8), respectively) (Fig. 7). These differences might 
be due to other parameters such as the animal species, 
age or physiological state. 
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